Pandemic Influenza Vaccine H5n1 Astrazeneca

A/Vietnam/1203/2004 (H5N1) strain, the active ingredient in Pandemic Influenza Vaccine H5n1 Astrazeneca, is a vaccine presented as a nasal spray for nasal use. It is intended to prevent pandemic influenza caused by the H5N1 virus in individuals at risk of exposure.

GNH USA supplies Pandemic Influenza Vaccine H5n1 Astrazeneca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. The company adheres to Good Distribution Practice standards and provides cold‑chain logistics for temperature‑sensitive biologics.

Pandemic Influenza Vaccine H5n1 Astrazeneca is an influenza vaccine used to prevent infection by H5N1 pandemic strains. - Pandemic influenza (H5N1): induces protective immunity to reduce the risk of infection. - Close contacts of confirmed H5N1 cases: provides prophylactic protection for exposed individuals. - Travelers to endemic regions: helps prevent H5N1 exposure during travel.

Common adverse reactions are generally mild and resolve without intervention.

Common Side Effects: - Nasal congestion or irritation. - Sore throat. - Mild fever. - Headache. - Runny nose. - Transient cough.

Serious or Rare Side Effects: - Anaphylactic reaction. - Severe allergic response (e.g., angioedema). - Guillain‑Barré syndrome. - Neurological events such as seizures. - High‑grade fever persisting >48 hours. - Thrombocytopenia.

Vaccination should be considered in the context of individual health status and potential contraindications. - Pregnancy: safety not established; consult a healthcare professional before use. - Immunocompromised patients: may exhibit reduced immune response. - Egg allergy: assess risk as the vaccine may contain trace egg proteins. - Recent receipt of another vaccine: separate administration by at least 14 days. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other biologics or immunomodulating agents, affecting efficacy or safety.

Major Interactions (Avoid): - Intravenous immunoglobulin (IVIG): can diminish vaccine‑induced immunity. - Live viral vaccines administered concurrently: may interfere with immune response. - Antiviral agents (e.g., oseltamivir) given within 48 hours of vaccination: may reduce immunogenicity.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs (e.g., methotrexate): may lower antibody production. - Systemic corticosteroids: could affect vaccine effectiveness. - Antihistamines: may mask mild allergic reactions post‑vaccination.